iCANsee

iCANsee is an Israeli biotech focused on developing topical, pharmaceutical-grade cannabinoid medicines for ophthalmic disorders. The company's core approach is a nano-encapsulation platform intended to improve cannabinoid penetration into ocular tissues and increase targeted bioavailability after topical administration. Publicly available descriptions position the company around eye pain, ocular inflammation, dry eye, uveitis, glaucoma, and macular degeneration, with an emphasis on cannabinoid-based eye drops and related ocular delivery products. Available evidence suggests the company is an early-stage, platform-oriented private company rather than a clinical-stage or commercial ophthalmology company.